On March 4, 2026, the U.S. Food and Drug Administration (FDA) issued final guidance outlining the general principles for planning, designing, analyzing, and reporting non-interventional studies that use real-world data (RWD) to assess the safety of medicines. The guidance applies to drugs, vaccines, and biological products and establishes regulatory expectations for postmarketing safety studies conducted by pharmaceutical and biologics sponsors.
The document standardizes how non-interventional studies should be conducted when using real-world data sources such as electronic health records and insurance claims, providing clarity on study design, methodology, and reporting practices. It replaces earlier draft guidance and withdraws the FDA’s May 2013 guidance on pharmacoepidemiologic safety studies using electronic healthcare datasets.
Details of the Update
The final guidance defines non-interventional studies as research approaches that observe outcomes without assigning specific treatments or interventions. These studies rely on real-world data collected during routine healthcare delivery.
The FDA recommends that sponsors begin by clearly formulating research questions and identifying appropriate real-world data sources that can support reliable safety assessments. The guidance also emphasizes the need to define study variables and endpoints precisely, ensuring that datasets and analytical approaches are suitable for the intended safety evaluation.
In addition, the document highlights the importance of addressing bias and confounding factors during study design and analysis. Sponsors are expected to incorporate methods to identify, assess, and mitigate potential sources of bias that may affect safety conclusions.
The FDA further outlines expectations for transparent study documentation and comprehensive reporting, including detailed descriptions of methodologies, data sources, and analytical approaches used in the study.
Effective Date
The FDA’s final guidance on non-interventional studies using real-world data became effective on March 4, 2026.
Why It Matters
This update provides regulatory clarity for the use of real-world data in postmarketing safety surveillance. By standardizing study design, bias management, and reporting practices, the guidance supports more consistent, reliable, and transparent safety evaluations while enabling efficient use of existing healthcare data sources.
Who This Is Relevant For
The guidance is relevant for teams involved in postmarketing surveillance and safety evaluation, includingRegulatory Affairs, Quality Assurance, Patient Safety, Legal and Compliance, Commercial or Marketing, and R&D functions within pharmaceutical and biologics organizations.
Next Steps
Organizations conducting non-interventional safety studies using real-world data should review current study protocols and methodologies to ensure alignment with the FDA’s updated expectations. Stakeholders should also evaluate documentation practices and reporting processes across relevant departments to confirm that study designs, data selection methods, and analytical approaches meet the new standards.
As regulatory agencies increasingly formalize expectations around real-world data and postmarket safety monitoring, organizations may benefit from tools that help track evolving regulatory guidance and operationalize compliance across global markets.
RegASK is a leading agentic AI regulatory intelligence and workflow orchestration platform that empowers global organizations in highly regulated sectors, including consumer products and life sciences, to proactively navigate complex regulatory landscapes. By combining advanced Agentic AI with experts in the loop, RegASK delivers timely predictive actionable insights and end-to-end automation, streamlining compliance processes, mitigating risks, and accelerating market access across more than 160 countries. Learn more or book a demo now.
FAQs
What is the FDA’s 2026 guidance on non-interventional studies using real-world data?
The guidance outlines general principles for planning, designing, analyzing, and reporting non-interventional studies that use real-world data to evaluate the safety of drugs, vaccines, and biological products in postmarketing settings.
What types of data are considered real-world data in this guidance?
The FDA identifies data sources such as electronic health records and insurance claims as examples of real-world data that can be used in non-interventional safety studies.
Does this guidance replace previous FDA recommendations?
Yes. The final guidance withdraws the FDA’s May 2013 guidance on pharmacoepidemiologic safety studies using electronic healthcare datasets and replaces earlier draft recommendations.
How can RegASK help companies monitor regulatory updates related to infant formulas?
RegASK helps organizations track evolving regulatory guidance, interpret compliance requirements, and streamline regulatory workflows, enabling regulatory, safety, and compliance teams to respond more efficiently to updates such as the FDA’s new guidance on real-world data studies.
Subscribe to the latest regulatory news
Curated newsletters
Relevant industry info
Access expert insights
